Compare Endeavour Silver Corp (EXK) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs ResMed Inc. — how do they compare? Endeavour Silver Corp trades at $8.65 (market cap $2.54B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 12.6× Endeavour Silver Corp's market cap, and ResMed Inc. pays a 1.16% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and ResMed Inc. for 51 Days on average.
| EXK | RMD | |
|---|---|---|
Market Cap | $2.54B | $31.89B |
Volume | 7,077,330 | 618,314 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $275.96 |
52-Week Low | $7.07 | $182.82 |
Typical Hold Time | 25 Days | 51 Days |
Enterprise Value | $2.54B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.57, up 3.0% today, amid a bearish technical signal from moving averages but with neutral oscillators. The company reported a net loss of $119.10 million in 2025, though 2026 projections show a turnaround to a $66 million profit. Recent news highlights operational progress at the Terronera and Kolpa mines, alongside temporary disruptions now resolved. Revenue grew from $467.50 million in 2025 to a projected $737 million in 2026, signaling strong operational expansion.
The outlook for EXK is cautiously optimistic, driven by production growth and favorable silver prices, but risks include operational volatility and high valuation multiples. Analysts are predominantly bullish, with 11 of 14 recommending Buy, citing the company's strategic mine developments and improving financial trajectory as key catalysts for potential upside.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
